• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Optimal treatment of actinic keratoses.光化性角化病的最佳治疗方法。
Clin Interv Aging. 2013;8:29-35. doi: 10.2147/CIA.S31930. Epub 2013 Jan 14.
2
[Diagnosis and treatment of actinic keratosis].[光化性角化病的诊断与治疗]
Duodecim. 2015;131(9):863-70.
3
[A plethora of choices: treating actinic keratoses].选择众多:治疗光化性角化病
Rev Med Suisse. 2020 Apr 1;16(688):646-650.
4
Management of patients with actinic keratoses.光化性角化病患者的管理
Br J Nurs. 2012;21(10):S27-30. doi: 10.12968/bjon.2012.21.Sup10.S27.
5
Therapeutic strategies for actinic keratoses--a systematic review.光化性角化病的治疗策略——系统评价。
Eur J Dermatol. 2013 Jan-Feb;23(1):14-32. doi: 10.1684/ejd.2013.1923.
6
Management of actinic keratosis.光化性角化病的管理
Drug Ther Bull. 2013 Jul;51(7):81-4. doi: 10.1136/dtb.2013.7.0193. Epub 2013 Jul 4.
7
Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.光化性角化病:光动力疗法、冷冻疗法、5-氟尿嘧啶、咪喹莫特、双氯芬酸,还是其他方法?事实与争议。
Clin Dermatol. 2013 Nov-Dec;31(6):712-7. doi: 10.1016/j.clindermatol.2013.05.007.
8
[Treatment of actinic keratoses in older adults].[老年人光化性角化病的治疗]
Dermatologie (Heidelb). 2023 Sep;74(9):663-669. doi: 10.1007/s00105-023-05208-4. Epub 2023 Aug 18.
9
Current issues in the management of actinic keratosis.光化性角化病治疗的当前问题。
J Am Acad Dermatol. 2013 Jan;68(1 Suppl 1):S28-38. doi: 10.1016/j.jaad.2012.09.051.
10
Current therapies for actinic keratosis.光化性角化病的现行疗法。
Int J Dermatol. 2020 Jun;59(6):677-684. doi: 10.1111/ijd.14767. Epub 2020 Feb 3.

引用本文的文献

1
Immunoexpression of Ki67, P16 and Beta-catenin in precursor lesions of cutaneous squamous cell carcinoma.Ki67、P16 和 Beta-catenin 在皮肤鳞状细胞癌前病变中的免疫表达。
Rom J Morphol Embryol. 2024 Jan-Mar;65(1):19-25. doi: 10.47162/RJME.65.1.03.
2
Number Bias in Clinicians' Documentation of Actinic Keratosis Removal.临床医生记录光化性角化病切除情况时的数字偏差。
J Clin Med. 2023 Dec 29;13(1):202. doi: 10.3390/jcm13010202.
3
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.用于光化性角化病预防和治疗的药物制剂:综述。
Int J Mol Sci. 2023 Mar 5;24(5):4989. doi: 10.3390/ijms24054989.
4
Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies.磨皮术和化学换肤术的保险覆盖范围:对58家美国保险公司的批判性分析
Cureus. 2022 Dec 31;14(12):e33184. doi: 10.7759/cureus.33184. eCollection 2022 Dec.
5
Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action.替拉替尼治疗光化性角化病:作用机制洞察
Clin Cosmet Investig Dermatol. 2022 Nov 16;15:2495-2506. doi: 10.2147/CCID.S374122. eCollection 2022.
6
Profile of Tirbanibulin for the Treatment of Actinic Keratosis.替拉瑞林治疗光化性角化病的概况
J Clin Aesthet Dermatol. 2022 Oct;15(10 Suppl 1):S3-S10.
7
[Potassium hydroxide 5 % solution in actinic keratosis : A novel therapeutic approach in the lesion-directed treatment].[5%氢氧化钾溶液治疗光化性角化病:一种皮损靶向治疗的新方法]
Hautarzt. 2021 Nov;72(11):975-983. doi: 10.1007/s00105-021-04888-0. Epub 2021 Aug 13.
8
Guidelines of care for the management of actinic keratosis: Executive summary.光化性角化病管理指南:执行摘要。
J Am Acad Dermatol. 2021 Oct;85(4):945-955. doi: 10.1016/j.jaad.2021.05.056. Epub 2021 Jun 7.
9
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.Toll 样受体 7/8 激动剂治疗药物及其递药系统的研究进展:从抗病毒制剂到疫苗佐剂。
Adv Drug Deliv Rev. 2021 Aug;175:113803. doi: 10.1016/j.addr.2021.05.013. Epub 2021 May 29.
10
Guidelines of care for the management of actinic keratosis.光化性角化病治疗管理指南。
J Am Acad Dermatol. 2021 Oct;85(4):e209-e233. doi: 10.1016/j.jaad.2021.02.082. Epub 2021 Apr 2.

本文引用的文献

1
What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents.现场定向治疗在光化性角化病治疗中的作用是什么?第一部分:概述与研究中的外用药物。
Cutis. 2012 May;89(5):241-50.
2
Can photodynamic therapy reverse the signs of photoageing and field cancerization?光动力疗法能逆转光老化和场癌化的迹象吗?
Br J Dermatol. 2012 Jul;167(1):2. doi: 10.1111/j.1365-2133.2012.10914.x.
3
Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study.同时使用外用 5-氟尿嘧啶乳膏和咪喹莫特乳膏治疗难治性光化性角化病:一项病例对照研究。
Dermatol Surg. 2012 Sep;38(9):1469-76. doi: 10.1111/j.1524-4725.2012.02480.x. Epub 2012 Jun 19.
4
Ingenol mebutate gel for actinic keratosis.咪喹莫特乳膏治疗光化性角化病。
N Engl J Med. 2012 Mar 15;366(11):1010-9. doi: 10.1056/NEJMoa1111170.
5
Zyclara (imiquimod) cream, 3.75%.3.75% 咪喹莫特乳膏(商品名:Zyclara)
Skinmed. 2010 Jul-Aug;8(4):227-9.
6
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.塞来昔布预防非黑素瘤皮肤癌的随机、双盲、安慰剂对照试验。
J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.
7
Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders.局部 5-氟尿嘧啶的作用机制:综述及在皮肤科疾病治疗中的意义。
J Dermatolog Treat. 2012 Apr;23(2):83-9. doi: 10.3109/09546634.2010.507704. Epub 2010 Oct 31.
8
A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.一项关于3.75%咪喹莫特乳膏在冷冻手术后治疗光化性角化病的随机、双盲、安慰剂对照、多中心疗效和安全性研究。
J Drugs Dermatol. 2010 Sep;9(9):1101-8.
9
Spreading pigmented actinic keratosis: a review.播散性色素性光化性角化病:综述。
J Am Acad Dermatol. 2010 Sep;63(3):499-506. doi: 10.1016/j.jaad.2009.07.026. Epub 2010 Mar 23.
10
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.咪喹莫特 2.5% 和 3.75% 乳膏用于治疗光化性角化病:两项为期 2 周、每日应用于面部和脱发头皮的安慰剂对照研究的结果。
J Am Acad Dermatol. 2010 Apr;62(4):582-90. doi: 10.1016/j.jaad.2009.07.004. Epub 2010 Feb 4.

光化性角化病的最佳治疗方法。

Optimal treatment of actinic keratoses.

机构信息

Department of Dermatology, Wayne State University School of Medicine, Detroit, MI, USA.

出版信息

Clin Interv Aging. 2013;8:29-35. doi: 10.2147/CIA.S31930. Epub 2013 Jan 14.

DOI:10.2147/CIA.S31930
PMID:23345970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3549675/
Abstract

The most compelling reason and primary goal of treating actinic keratoses is to prevent malignant transformation into invasive squamous cell carcinoma, and although there are well established guidelines outlining treatment modalities and regimens for squamous cell carcinoma, the more commonly encountered precancerous actinic lesions have no such standard. Many options are available with variable success and patient compliance rates. Prevention of these lesions is key, with sun protection being a must in treating aging patients with sun damage as it is never too late to begin protecting the skin.

摘要

治疗光化性角化病最有说服力的原因和主要目标是防止恶性转化为侵袭性鳞状细胞癌,虽然已经有明确的指南概述了鳞状细胞癌的治疗方式和方案,但更常见的癌前光化性病变没有这样的标准。有许多可供选择的方法,成功率和患者依从率各不相同。预防这些病变是关键,对于因日晒而受损的老年患者,防晒是必须的,因为保护皮肤永远不会太晚。